News
Zacks Investment Research on MSN10h
AbbVie's Rinvoq Gets EU Nod for 8th Indication Giant Cell ArteritisAbbVie ABBV announced that the European Commission has granted marketing approval to its blockbuster drug Rinvoq for treating ...
AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization to RINVOQ� (upadacitinib; 15 mg, once daily) for the treatment of giant cell arteritis (GCA) in ...
RINVOQ is the first and only oral Janus kinase (JAK) inhibitor approved in the European Union (EU) to treat adult patients with giant cell arteritis (GCA) The approval ...
Vanrafia, 2nd drug in Novartis' IgAN troika, crosses FDA finish line in payday for Chinook investors
When Novartis bought kidney disease biotech Chinook Therapeutics in 2023 for $3.2 billion upfront, the deal included a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback